166 related articles for article (PubMed ID: 37543103)
1. Biologic Choice Should Be Guided by Disease Severity Not Malignancy in Patients With Inflammatory Bowel Disease.
Zhou A; Srinivasan A; Vasudevan A
Clin Gastroenterol Hepatol; 2024 Mar; 22(3):670-672. PubMed ID: 37543103
[No Abstract] [Full Text] [Related]
2. Updates in diagnosis and management of inflammatory bowel disease.
Sandberg K; Yarger E; Saeed S
Curr Probl Pediatr Adolesc Health Care; 2020 May; 50(5):100785. PubMed ID: 32402535
[TBL] [Abstract][Full Text] [Related]
3. Peripheral Blood Monocytosis Is Associated With Long-Term Disease Severity in Pediatric-Onset Inflammatory Bowel Disease.
Zhang X; Ramos-Rivers C; Prathapan K; Wang X; Tang G; Kim S; Binion DG
J Pediatr Gastroenterol Nutr; 2023 Jun; 76(6):756-762. PubMed ID: 36827967
[TBL] [Abstract][Full Text] [Related]
4. Endoscopic Disease Activity and Biologic Therapy Are Independent Predictors of Suboptimal Bowel Preparation in Patients with Inflammatory Bowel Disease Undergoing Colonoscopy.
Kumar A; Shenoy V; Buckley MC; Durbin L; Mackey J; Mone A; Swaminath A
Dig Dis Sci; 2022 Oct; 67(10):4851-4865. PubMed ID: 35624326
[TBL] [Abstract][Full Text] [Related]
5. Precision Medicine in Inflammatory Bowel Diseases.
Fischer S; Neurath MF
Clin Pharmacol Ther; 2017 Oct; 102(4):623-632. PubMed ID: 28699158
[TBL] [Abstract][Full Text] [Related]
6. Biologic therapy in inflammatory bowel disease.
Loftus EV
Gastroenterol Clin North Am; 2014 Sep; 43(3):xv-xvii. PubMed ID: 25110264
[No Abstract] [Full Text] [Related]
7. [Histopathology of IBD: What clinicians do expect in 2017?].
Savoye G
Ann Pathol; 2017 Aug; 37(4):277-278. PubMed ID: 28823311
[No Abstract] [Full Text] [Related]
8. Endoscopy in inflammatory bowel diseases.
Hommes DW; van Deventer SJ
Gastroenterology; 2004 May; 126(6):1561-73. PubMed ID: 15168367
[TBL] [Abstract][Full Text] [Related]
9. Choosing the right biologic for complications of inflammatory bowel disease.
Rakowsky S; Papamichael K; Cheifetz AS
Expert Rev Gastroenterol Hepatol; 2022 Mar; 16(3):235-249. PubMed ID: 35094628
[TBL] [Abstract][Full Text] [Related]
10. MR enterography of extraluminal manifestations of inflammatory bowel disease in children and adolescents: moving beyond the bowel wall.
Smith EA; Dillman JR; Adler J; Dematos-Maillard VL; Strouse PJ
AJR Am J Roentgenol; 2012 Jan; 198(1):W38-45. PubMed ID: 22194513
[TBL] [Abstract][Full Text] [Related]
11. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
Borren NZ; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
[TBL] [Abstract][Full Text] [Related]
12. Two cases of hepatoid adenocarcinoma of the intestine in association with inflammatory bowel disease.
Liu Q; Bannan M; Melamed J; Witkin GB; Nonaka D
Histopathology; 2007 Jul; 51(1):123-5. PubMed ID: 17532770
[No Abstract] [Full Text] [Related]
13. Why innovation in inflammatory bowel disease drug development will impact your practice.
Sandborn WJ
Clin Gastroenterol Hepatol; 2011 Mar; 9(3):211-3. PubMed ID: 21338946
[No Abstract] [Full Text] [Related]
14. Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study.
Seishima R; Okabayashi K; Ikeuchi H; Uchino M; Futami K; Noguchi T; Ohge H; Iseki Y; Watanabe K; Itabashi M; Okamoto K; Toiyama Y; Ogino T; Nakamura M; Yamada K; Wakai T; Sato Y; Kimura H; Takahashi K; Hida K; Kinugasa Y; Ishida F; Okuda J; Daito K; Koyama F; Ueno H; Yamamoto T; Yamamoto S; Hanai T; Maemoto A; Arakaki J; Komori K; Akagi Y; Shida D; Yamaguchi S; Matsuda K; Maeda K; Noake T; Nezu R; Sasaki S; Hasegawa J; Sunami E; Kanemitsu Y; Katsumata K; Uehara K; Kiyomatsu T; Suto T; Kazama S; Yamada T; Goi T; Ishihara S; Ajioka Y; Sugihara K
Am J Gastroenterol; 2023 Jul; 118(7):1248-1255. PubMed ID: 36622356
[TBL] [Abstract][Full Text] [Related]
15. Biologic drugs for inflammatory bowel disease.
Yanai S; Matsumoto T
Nihon Rinsho; 2017 Mar; 75(3):403-407. PubMed ID: 30566782
[TBL] [Abstract][Full Text] [Related]
16. Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment?
Egan C; Doherty GA
Expert Opin Biol Ther; 2019 Sep; 19(9):907-918. PubMed ID: 31046477
[No Abstract] [Full Text] [Related]
17. Switching biologics used in inflammatory bowel diseases: how to deal with in practice?
Liefferinckx C; Cremer A; Franchimont D
Curr Opin Pharmacol; 2020 Dec; 55():82-89. PubMed ID: 33166871
[TBL] [Abstract][Full Text] [Related]
18. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
Shah ED; Coburn ES; Nayyar A; Lee KJ; Koliani-Pace JL; Siegel CA
Aliment Pharmacol Ther; 2020 Mar; 51(5):527-533. PubMed ID: 31990422
[TBL] [Abstract][Full Text] [Related]
19. Endoscopy in Inflammatory Bowel Disease.
Klinger AL; Kann BR
Surg Clin North Am; 2019 Dec; 99(6):1063-1082. PubMed ID: 31676048
[TBL] [Abstract][Full Text] [Related]
20. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
Gu P; Luo J; Kim J; Paul P; Limketkai B; Sauk JS; Park S; Parekh N; Zheng K; Rudrapatna V; Syal G; Ha C; McGovern DP; Melmed GY; Fleshner P; Eisenstein S; Ramamoorthy S; Dulai PS; Boland BS; Grunvald E; Mahadevan U; Ohno-Machado L; Sandborn WJ; Singh S
Am J Gastroenterol; 2022 Oct; 117(10):1639-1647. PubMed ID: 35973139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
